[go: up one dir, main page]

HK1089106A1 - Fentanyl salt composition for nasal administration - Google Patents

Fentanyl salt composition for nasal administration

Info

Publication number
HK1089106A1
HK1089106A1 HK06110676.4A HK06110676A HK1089106A1 HK 1089106 A1 HK1089106 A1 HK 1089106A1 HK 06110676 A HK06110676 A HK 06110676A HK 1089106 A1 HK1089106 A1 HK 1089106A1
Authority
HK
Hong Kong
Prior art keywords
fentanyl
administration
nasal administration
salt composition
nasal
Prior art date
Application number
HK06110676.4A
Other languages
English (en)
Inventor
Jesper Grarup
Hanne Wulff Nielsen
Original Assignee
Takeda Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1089106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharma As filed Critical Takeda Pharma As
Publication of HK1089106A1 publication Critical patent/HK1089106A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06110676.4A 2000-07-31 2006-09-25 Fentanyl salt composition for nasal administration HK1089106A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200001154 2000-07-31

Publications (1)

Publication Number Publication Date
HK1089106A1 true HK1089106A1 (en) 2006-11-24

Family

ID=8159630

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110676.4A HK1089106A1 (en) 2000-07-31 2006-09-25 Fentanyl salt composition for nasal administration

Country Status (24)

Country Link
US (3) US8017627B2 (pt)
EP (3) EP1642578B2 (pt)
JP (2) JP4898073B2 (pt)
KR (2) KR20080053423A (pt)
CN (2) CN100346788C (pt)
AT (1) ATE388705T1 (pt)
AU (2) AU2001281746C1 (pt)
CA (1) CA2417727C (pt)
CY (2) CY1107405T1 (pt)
DE (2) DE60133203T3 (pt)
DK (2) DK1642578T3 (pt)
EA (1) EA006384B1 (pt)
EE (1) EE05420B1 (pt)
ES (2) ES2302742T5 (pt)
HK (1) HK1089106A1 (pt)
IL (2) IL154041A0 (pt)
IS (1) IS2803B (pt)
NO (2) NO330565B1 (pt)
NZ (1) NZ524396A (pt)
PL (1) PL207845B1 (pt)
PT (2) PT1642578E (pt)
SI (2) SI1307194T2 (pt)
UA (2) UA77398C2 (pt)
WO (1) WO2002009707A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
DE60133203T3 (de) 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
MX2008012922A (es) * 2006-04-13 2008-12-17 Nupathe Inc Metodos y sistemas transdermicos para la entrega de compuestos contra migraña.
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2009070829A1 (en) * 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
WO2012024595A2 (en) 2010-08-20 2012-02-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
ES2592259T3 (es) 2011-02-04 2016-11-29 Archimedes Development Limited Contenedor mejorado
JP6339371B2 (ja) 2011-03-03 2018-06-06 インペル ニューロファーマ インコーポレイテッド 経鼻薬物送達デバイス
EP3851142A1 (en) 2011-05-09 2021-07-21 Impel NeuroPharma Inc. Nozzles for nasal drug delivery
TR201802716T4 (tr) * 2011-05-13 2018-03-21 Euro Celtique Sa Nalokson içeren intranazal farmasötik dozaj formları.
JP2016520378A (ja) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド 医用単位用量コンテナ
AU2015369710B2 (en) 2014-12-23 2020-09-17 Vertical Pharmaceuticals, Llc Systems, devices and methods for dispensing oral transmucosal dosage forms
EP3341059B1 (en) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. In-line nasal delivery device
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
JP2021503988A (ja) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド インレットインターフェースを用いた鼻腔内装置
KR20200118034A (ko) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 올란자핀의 비강내 전달
JP7317020B2 (ja) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
NZ777687A (en) 2019-01-03 2023-12-22 Impel Pharmaceuticals Inc Nasal drug delivery device
KR20220010011A (ko) 2019-05-17 2022-01-25 임펠 뉴로파마 인코포레이티드 일회용 비강 전달 장치
WO2022038403A1 (ru) 2020-10-15 2022-02-24 Владимир ТИМКО Фармацевтическая композиция на основе налбуфина и/или его солей для назального применения

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4916142A (en) 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5028616A (en) 1989-09-05 1991-07-02 G. D. Searle & Co. N-benzylpiperidine amides
US5098915A (en) 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
USRE38407E1 (en) 1994-03-23 2004-01-27 Delex Therapeutics Inc. Pain management with liposome-encapsulated analgesic drugs
WO1995031182A1 (en) * 1994-05-13 1995-11-23 Aradigm Corporation Narcotic containing aerosol formulation
DE19536246A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
DE122006000022I1 (de) 1995-06-05 2006-09-21 Alza Corp Vorrichtung zur Transdermalen iontophoretischen verabreichung von Fentanyl und Sufentanil
ZA964320B (en) 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
CN1122540C (zh) * 1995-06-07 2003-10-01 亚历山大·乔治·布赖恩·奥尼尔 由病人控制的药物输送装置
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6645980B1 (en) 2000-05-25 2003-11-11 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6663883B1 (en) 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
US7074803B2 (en) 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
WO2002011778A1 (en) 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US7049326B2 (en) 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
WO2001097780A2 (en) 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE60133203T3 (de) 2000-07-31 2012-02-23 Nycomed Danmark Aps Fentanyl Zusammensetzung für nasale Anwendung
US20020106407A1 (en) 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
JP4850346B2 (ja) 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
FR2829757B1 (fr) * 2001-09-20 2004-07-09 Commissariat Energie Atomique Procede de preparation d'un sol stable de zircono-titanate de plomb et procede de preparation de films a partir dudit sol
WO2004006929A1 (ja) 2002-07-11 2004-01-22 Taiho Pharmaceutical Co., Ltd. 経鼻吸収用組成物
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20060062812A1 (en) 2003-03-11 2006-03-23 Calvin Ross Novel compositions
PT1638933E (pt) 2003-06-17 2008-07-22 Pfizer Derivados de n-pirrolidin-3-il-amida como inibidores de recaptação de serotonina e noradrenalina
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
NZ569949A (en) 2006-01-25 2011-10-28 Insys Therapeutics Inc Sublingual fentanyl spray
WO2009047779A2 (en) 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
NO2180844T3 (pt) 2007-08-02 2018-07-21
WO2009070829A1 (en) 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration

Also Published As

Publication number Publication date
EP1642578A2 (en) 2006-04-05
NO333809B1 (no) 2013-09-23
KR20030034126A (ko) 2003-05-01
EP1642578A3 (en) 2006-09-27
NO20110342L (no) 2003-03-31
IS6702A (is) 2003-01-28
AU2001281746C1 (en) 2010-09-09
US8017627B2 (en) 2011-09-13
IS2803B (is) 2012-09-15
CN101181241A (zh) 2008-05-21
PT1307194E (pt) 2008-05-27
ES2427976T5 (es) 2022-04-13
ES2302742T3 (es) 2008-08-01
CY1114645T1 (el) 2016-10-05
EA006384B1 (ru) 2005-12-29
EE200300050A (et) 2004-12-15
UA89755C2 (ru) 2010-03-10
CA2417727A1 (en) 2002-02-07
US8653107B2 (en) 2014-02-18
NZ524396A (en) 2003-09-26
JP2008044951A (ja) 2008-02-28
JP4898073B2 (ja) 2012-03-14
EP1307194B2 (en) 2011-04-27
IL154041A (en) 2011-05-31
DK1307194T3 (da) 2008-07-14
NO20030365L (no) 2003-03-31
EP1307194A1 (en) 2003-05-07
DK1307194T4 (da) 2011-07-18
ES2427976T3 (es) 2013-11-05
CA2417727C (en) 2009-09-01
ES2302742T5 (es) 2011-10-10
EP2255806A3 (en) 2011-06-29
WO2002009707A1 (en) 2002-02-07
NO20030365D0 (no) 2003-01-24
EP1642578B2 (en) 2021-11-03
IL154041A0 (en) 2003-07-31
AU8174601A (en) 2002-02-13
US20040034059A1 (en) 2004-02-19
AU2001281746B2 (en) 2006-10-05
DK1642578T3 (da) 2013-08-12
NO330565B1 (no) 2011-05-16
DE60133203D1 (de) 2008-04-24
CN100346788C (zh) 2007-11-07
SI1642578T1 (sl) 2013-10-30
EA200300201A1 (ru) 2003-06-26
US20110281914A1 (en) 2011-11-17
US8158651B2 (en) 2012-04-17
PL207845B1 (pl) 2011-02-28
SI1307194T2 (sl) 2011-07-29
DE20122843U1 (de) 2008-06-26
UA77398C2 (en) 2006-12-15
SI1307194T1 (sl) 2008-08-31
EE05420B1 (et) 2011-06-15
EP1642578B1 (en) 2013-07-03
KR100888275B1 (ko) 2009-03-10
EP2255806A2 (en) 2010-12-01
SI1642578T2 (sl) 2022-01-31
US20070134164A1 (en) 2007-06-14
DE60133203T2 (de) 2009-04-30
JP2004505052A (ja) 2004-02-19
ATE388705T1 (de) 2008-03-15
CY1107405T1 (el) 2012-12-19
KR20080053423A (ko) 2008-06-12
DE60133203T3 (de) 2012-02-23
PL365053A1 (en) 2004-12-27
PT1642578E (pt) 2013-09-30
EP1307194B1 (en) 2008-03-12
CN1466455A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
HK1089106A1 (en) Fentanyl salt composition for nasal administration
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
MXPA04006395A (es) Una formulacion farmaceutica liquida que comprende nicotina para la administracion en la cavidad oral.
SI1572167T1 (sl) Transdermalni buprenorfinski dozirni reĹľim za analgezijo
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
NZ326345A (en) Composition containing diosgenin
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
MXPA03010407A (es) Prevencion de adiccion en gestion del dolor.
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
AU2002214030A1 (en) Novel medicament compositions consisting of tiotropium salts and antihistamines for treating respiratory illnesses
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
WO2006024044A8 (en) Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210730